| 0.998 Data as of May 23 |  -0.052 / -4.95%Today’s Change | 0.75 Today|||52-Week Range 1.84 | -5.85% Year-to-Date |
| SECTOR Electronic Technology | INDUSTRY Electronic Equipment/Instruments | MARKET CAP $57.8M |
Company Description
Implant Sciences Corp. develops and manufactures explosive trace detection sensors and systems that are capable of detecting minute amounts of a wide variety of military, commercial, and homemade explosives. The company has developed proprietary technologies used in its commercial explosives and drugs trace detection systems that ship to a growing number of locations internationally. Its products are Quantum Sniffer QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and the company's QS-B220 bench top explosives and narcotics trace detector has received a Developmental Testing & Evaluation Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002. The company was founded in August 1984 and is headquartered in Wilmington, MA.
Employees
Shareholders
| Individual stakeholders | 6.79% |
| Mutual fund holders | -- |
| Other institutional | -- |
Top Executives
| Glenn D. Bolduc | Chairman, President, CEO & Head-Investor Relations |
| William J. McGann, PhD | Chief Operating Officer & Director |
| Roger P. Deschenes | Chief Financial Officer & Vice President |
| Hacene Boudries, PhD | Technology Director |
| Andrew Anderson | Engineering Director |
.
